COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO A SUBSTANCE USE DISORDER
The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.
1 . (canceled)
2 . A method for determining an appropriate treatment for a subject that has, or is at risk for developing a dependence on tobacco, comprising: (a) providing a biological sample from the subject; (b) contacting DNA from the biological sample with bisulfite under alkaline conditions; (c) contacting the bisulfite-treated DNA with at least one first oligonucleotide probe at least 7 nucleotides in length that is complementary to a bisulfite-converted nucleic acid sequence that, prior to bisulfite-conversion, comprises a CpG dinucleotide at position 233284661 of chromosome 2, wherein the at least one first oligonucleotide probe detects an unmethylated CpG dinucleotide at position 233284661 of chromosome 2, (d) detecting a methylation status of the CpG dinucleotide, wherein the methylation status of the CpG dinucleotide at position 233284661 of chromosome 2 is associated with the use of tobacco by the subject, and (e) determining the appropriate treatment for the subject.
3 . The method of claim 2 , wherein the biological sample is peripheral blood.
4 . The method of claim 2 , wherein the biological sample is lymphocytes.
5 . The method of claim 2 , further comprising contacting the bisulfite-treated DNA with at least one second oligonucleotide probe at least 7 nucleotides in length that is complementary to the bisulfite-converted nucleic acid sequence that comprises the CpG dinucleotide at position 233284661 of chromosome 2, wherein the at least one second oligonucleotide probe detects a methylated CpG dinucleotide at position 233284661 of chromosome 2.
6 . The method of claim 5 , further comprising determining a ratio of methylated CpG dinucleotides to unmethylated CpG dinucleotides at position 233284661 of chromosome 2.
7 . The method of claim 2 , further comprising, after step (c), amplifying the nucleic acid.
8 . The method of claim 2 , further comprising, after step (c), sequencing the nucleic acid.
9 . The method of claim 2 , wherein the at least one first oligonucleotide probe is 7 to 50 nucleotides in length.
10 . The method of claim 2 , wherein the at least one first oligonucleotide probe is 10 to 40 nucleotides in length.
11 . The method of claim 2 , wherein the at least one first oligonucleotide probe is 15 to 35 nucleotides in length.
12 . The method of claim 2 , wherein the at least one first oligonucleotide probe is 10 nucleotides in length.
13 . The method of claim 2 , wherein the at least one first oligonucleotide probe is 15 nucleotides in length.